Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: A voxel-based analysis study. by Mallik, S et al.
Multiple Sclerosis Journal
2015, Vol. 21(4) 423 –432
DOI: 10.1177/ 
1352458514546513
© The Author(s), 2014.  
Reprints and permissions:  
http://www.sagepub.co.uk/ 
journalsPermissions.nav
MULTIPLE
SCLEROSIS MSJ
JOURNAL
http://msj.sagepub.com 423
Introduction
In multiple sclerosis (MS), grey matter (GM) demyeli-
nation and neuro-axonal loss are all recognised histo-
pathological features.1 Cortical demyelination can be 
seen in the earliest clinical stages of MS,2 and may be 
extensive in progressive forms of the disease.3,4 
Similarly, GM neuro-axonal loss, especially in the deep 
GM structures, can be seen early in MS,5 and is evident 
in the cortex later in the course of the disease.6–8
It is not known how closely GM demyelination and 
neuro-axonal loss are related. One histopathological 
study using material from 22 people with MS (clinical 
sub-types were not specified) found no clear associa-
tion between local cortical demyelination and cortical 
thickness, although neuronal densities were reduced 
in leucocortical lesions.6 More recently, evidence has 
emerged that meningeal inflammation is linked with 
both cortical demyelination,8–10 and neuro-axonal 
loss.7 Such meningeal inflammation appears to be par-
ticularly apparent in secondary progressive (SPMS) 
and primary progressive (PPMS) subgroups.8–10 In 
spite of these observations, it is uncertain to what 
extent GM demyelination and neuro-axonal loss are 
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spatially co-localised and whether or not they are 
caused by a common pathological process. It is also 
not known if links (if present) between local demyeli-
nation and neuro-axonal loss occur in all MS 
subtypes.
Brain GM atrophy, which is associated with neuro-
axonal loss,11 can be detected using magnetic reso-
nance imaging (MRI), and appears to have a greater 
impact on clinical disability in the long-term than 
white matter (WM) lesion accrual.12–14 However, GM 
atrophy is not uniform throughout the brain, with 
some regions more frequently affected than oth-
ers,15,16 and this may vary between different MS phe-
notypes.17 Magnetisation transfer (MT) imaging 
provides insight into intrinsic structural tissue abnor-
malities. In WM, the MT ratio (MTR) is reduced in 
the presence of demyelination, and to a lesser degree 
axonal loss,18 and in the cortex has also been shown to 
reflect predominantly demyelination.19 Abnormal 
GM MTR has been shown even in the earliest stages 
of MS, correlating with disease duration,20 clinical 
disability21 and cognitive impairment.22
Voxel-based analysis (VBA) is a fully automated 
technique which allows whole-brain comparisons to 
be made between subject groups on a voxel-wise 
basis, via spatial transformation of images to a nor-
malised template. This method differs from region of 
interest (ROI) and histogram-based methods in that it 
allows unbiased assessment of the whole brain, 
detecting region specific changes between subject 
groups without first having to define the location and 
shape of the regions to be assessed.23,24 VBA methods 
allow the detection of significant regional effects 
within one group compared to another, identifying 
regions where the majority of participants in one 
group significantly differ from another group. Voxel-
based morphometry (VBM) specifically allows the 
volume of GM to be compared between subject 
groups at a voxel-by-voxel level, and is used to quan-
tify atrophy.25 Previous voxel-based studies have 
demonstrated regional MTR reductions in some areas 
in relapsing–remitting MS (RRMS) (insula and len-
ticular nuclei bilaterally, as well as the left posterior 
cingulate cortex, and the right orbitofrontal cortex).26 
In one study of people with PPMS, MTR changes 
were found to co-localise with atrophy in small GM 
regions,27 but MTR reductions were also seen in areas 
without GM atrophy, and in the majority of cases co-
localisation in GM was not observed.
To date, no studies have systematically assessed 
regional GM atrophy and MTR abnormalities across 
RRMS, PPMS and SPMS patients. In this study we 
undertook VBA of brain GM atrophy and MTR in a 
relatively large cohort of people with MS including 
all three subgroups. Using VBA to identify regions 
of the brain that are consistently affected in each 
group, we sought to answer the following 
questions:
1. Does atrophy, suggesting neuro-axonal loss, 
demonstrate different spatial patterns of corti-
cal and deep GM involvement in different clin-
ical subgroups of MS?
2. Does MTR reduction, suggesting demyelina-
tion, demonstrate different spatial patterns of 
cortical and deep GM involvement in different 
clinical subgroups of MS?
3. To what extent do atrophy and MTR reduc-
tion occur in the same regions in the cortical 
and deep GM of different clinical subgroups 
of MS?
Methods
Subjects
We recruited people with clinically definite MS28 
who had not experienced a relapse or received cor-
ticosteroids in the four weeks prior to the study. We 
also recruited healthy controls with no history of 
neurological or psychiatric disorders. All partici-
pants gave informed consent before taking part in 
this study. This study was approved by the local 
institutional research ethics committee. All partici-
pants had a clinical assessment to confirm the clini-
cal subtype of MS, disease duration, and disability 
as measured using the Expanded Disability Status 
Scale (EDSS).
MRI acquisition
Images were acquired using a 3T Philips Achieva 
scanner (Philips Healthcare, Best, The Netherlands) 
with a 32-channel head coil and multi-transmit tech-
nology. T1-weighted (T1w) volumetric and MT 
images were obtained sagittally, with a field-of view 
of 256×256×180 mm3 and 1 mm isotropic resolution 
with the following parameters: T1w volumes, using 
a 3D inversion-prepared (TI=824 ms) gradient echo 
[Fast Field Echo (FFE)] sequence [Repetition Time 
(TR)=6.9ms; Echo Time (TE)=3.1ms]; flip angle 
(α)=8°; MTR data, using a 3D slab selective spoiled 
gradient echo (FFE) sequence with two echoes 
(TR=6.4 ms, TE1/TE2=2.7/4.3 ms, α=9°) with and 
without sinc-Gaussian shaped MT saturating pulses 
of nominal α=360°, offset frequency 1 kHz, duration 
16 ms applied prior to the excitation pulse.
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Image analysis
NiftyReg29 was used to affine register the MT-on and 
MT-off images to the T1w volume. MTR maps were 
calculated using the equation
MTR=(MT-off–MT-on)/MT-off
WM lesion-filled T1w images30 were segmented 
using the ‘New Segment’ function in SPM8 (UCL 
Wellcome Trust Centre for Neuroimaging, London, 
UK). The resulting GM tissue probability maps were 
all checked for accuracy and then used in two ways. 
First, they were binarised using a conservative 90% 
threshold, and overlaid on the MTR map to define 
GM regions to be included in the subsequent VBM 
analysis. The binarised GM volumes for each indi-
vidual subject were divided by their respective intrac-
ranial volumes (ICVs), calculated by summing the 
GM, WM and Cerebrospinal Fluid (CSF) volumes, to 
calculate the GM fraction (GMf). Second, the proba-
bility maps were used to create a custom diffeomor-
phic anatomical registration using exponentiated Lie 
algebra (DARTEL) template using SPM8.31 Each par-
ticipant’s GM probability map was registered to this 
template using a non-linear transformation, and then 
affine transformed into Montreal Neurological 
Institute (MNI) space with sinc interpolation, before 
being smoothed with an 8 mm full width half maxi-
mum (FWHM) Gaussian smoothing kernel. Each par-
ticipant’s segmented GM MTR map was then 
transformed to MNI space via the DARTEL template 
using the same transformations in a single step with 
sinc interpolations. The MTR maps were then 
smoothed using an 8 mm FWHM Gaussian smooth-
ing kernel. We calculated the global mean GM MTR 
value for the segmented MTR maps using the ‘fslstats’ 
command from the FSL suite (FMRIB Software 
Library, Oxford).32 Also using ‘fslstats’, we calcu-
lated mean voxel counts for the cortical and deep GM 
compartments for each group, from the thresholded 
(90%) T1w GM segmentations.
Statistical analysis
Using Stata 13.1 (Stata Corporation, College Station, 
Texas, USA), comparison of means between the sub-
ject groups was performed using a multiple regression 
for each response variable (age, duration and global 
GM MTR) regressed on three group indicators (RR, 
PP, SP) with controls as the reference group. Using 
this model, joint tests were performed with the null 
hypothesis that all groups demonstrated the same 
mean; if this null hypothesis was rejected, individual 
group comparisons were performed from the same 
model estimates. In the case of global GM MTR, 
adjustment was made for age, duration and gender 
which were entered as covariates. Volumetric and 
MTR VBA was performed using SPM8. Areas of 
abnormality were considered statistically significant at 
an alpha threshold of p=0.05, corrected for multiple 
comparisons using Gaussian random field theory 
(family wise error (FWE)) at voxel level. Age and gen-
der were included as covariates in the general linear 
models. We also performed analysis at p=0.001 uncor-
rected, for comparison. We used the Wake Forest 
University (WFU) biological parametric mapping 
(BPM beta version 1.5d) toolbox for SPM5 to perform 
a voxel-by-voxel correlation analysis of MTR and vol-
ume within each clinical subgroup, at FWE (p=0.05).33
Identification and quantification of affected voxels
When comparing each of the three MS clinical sub-
groups with controls, and comparing the clinical sub-
groups with each other, we used MRIcron34 to (a) label 
regions of consistent MTR reduction, (b) label regions 
of consistent atrophy, (c) label regions where MTR 
reduction and atrophy co-localised, and (d) count the 
number of voxels affected by each pathological pro-
cess in each region. This was done by overlaying 
the images of significant clusters from SPM8 onto the 
Automated Anatomical Labeling (AAL) atlas.35 The 
same method was used to identify voxels demonstrat-
ing correlation between MTR and volume in the GM.
Results
Participant characteristics
A total of 98 patients and 29 healthy controls were 
included in the study. Of the patients, 51 had RRMS, 
28 had SPMS, and 19 had PPMS. Participant charac-
teristics are summarised in Table 1. The joint tests 
from a single model for the null hypothesis that all 
subject groups had the same mean age and duration 
were rejected (p<0.0001). Overall, all MS subgroups 
were older than controls (p<0.001). People with 
RRMS were significantly younger than people with 
SPMS (p<0.001) and PPMS (p<0.001). There was no 
significant difference in age between the SPMS and 
PPMS groups (p=0.642). The SPMS group had a sig-
nificantly longer mean disease duration than either 
PPMS (p=0.001), or RRMS (p<0.001). There was no 
significant difference in mean duration between 
RRMS and PPMS (p=0.348). The joint test from a 
single model for the null hypothesis that all subject 
groups had the same mean global GM MTR, when 
adjusted for age, duration and gender was rejected 
(p<0.0001). Adjusting for age, duration and gender, 
there was a significant difference in the global GM 
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MTR between all MS subgroups and controls 
(p<0.001), RRMS and SPMS (p<0.001), SPMS and 
PPMS (p<0.001), but no significant difference 
between RRMS and PPMS (p=0.104).
Clinical subgroups compared to controls
A summary of results can be seen in Table 2, showing 
voxel counts for MTR reduction, and atrophy, in the 
total GM, in the cortex, in the deep GM, for the differ-
ent clinical subgroups in MS compared with healthy 
controls.
MTR reduction. Significant regional MTR reductions 
were seen in the GM of all clinical subgroups com-
pared to controls, but were more extensive in SPMS 
(13,109 voxels) than in RRMS (3615 voxels) and 
PPMS (3825 voxels). The absolute numbers of voxels 
demonstrating MTR reduction was more in the cortex 
than in the deep GM in PPMS and SPMS, while in 
RRMS the deep GM areas were proportionately more 
affected. The precise regions of cortical and deep GM 
MTR reduction for each clinical subgroup, compared 
to controls, are summarised in Supplementary Mate-
rial, Appendices 1 and 2.
Atrophy. Compared to controls, the number of voxels 
demonstrating regional atrophy was more extensive 
in RRMS (5026 voxels) and SPMS (1538 voxels) 
than in the PPMS group (no significant regional atro-
phy compared to controls). Deep GM atrophy 
accounted for most of the regional atrophy seen in 
RRMS and SPMS. The areas of cortical and deep GM 
atrophy for each clinical subgroup, compared to 
Table 1. Participant characteristics.
RR SP PP Controls
n (males) 51 (19) 28 (7) 19 (8) 29 (13)
Mean age (years) 42.35 53.43 52.05 36.97
SD 9.84 7.73 9.48 12.04
Range 21–64 36–65 27–65 22–63
Mean duration (years) 11.85 22.73 13.53 –
SD 9.09 11.16 7.97 –
Range 0.5–45.0 7.5–47.83 2.5–27.25 –
Median EDSS 2.0 6.5 6.0 –
Range 1.0–7.0 4.0–8.5 1.5–6.5 –
Use of DMT 40 13 3 –
Current use 29 7 1 –
Previous use 11 6 2 –
Mean GM MTR 30.74 29.78 30.23 31.86
SD 1.211 1.141 1.498 0.566
Mean cortical voxels 538,477 499,893 546,057 560,602
SD 52,443 56,478 61,745 55,194
Mean deep GM voxels 23,446 21,927 24,840 26,353
SD 3025 2943 2680 2599
DMT: disease modifying therapy; EDSS: Expanded Disability Status Score; GM: grey matter; GMf: grey matter fraction; MTR: 
magnetisation transfer ratio; PP: Primary progressive; RR: Relapsing–remitting; SD: standard deviation; SP: secondary progressive.
Table 2. Voxel-based analysis (VBA) significant voxel counts (compared with controls) by clinical subgroup and 
location (family wise error (FWE) 0.05).
Overall MTR reduction Overall atrophy
 RR SP PP RR SP PP
Total 3615 13109 318 5026 1538 0
Cortex 399 9320 318 206 117 0
Deep GM 3216 3789 0 4820 1421 0
GM: grey matter; MTR: magnetisation transfer ratio; PP: primary progressive; RR: relapsing–remitting; SP: secondary progressive.
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controls, are summarised in Supplementary Material, 
Appendices 3 and 4.
Subgroup comparison
At FWE 0.05, we detected only a small difference in 
MTR reduction in the SPMS versus RRMS subgroup 
comparison (124 voxels), but did not detect any sig-
nificant differences in the other inter-subgroup com-
parisons for MTR reduction or atrophy alone, or 
co-localisation of both.
Controls compared to all patients and clinical 
subtypes
Controls did not show any areas of consistent MTR 
reduction, atrophy, or co-localisation in GM com-
pared to all patients, or to PPMS, SPMS and RRMS 
subgroups
Re-analysis without FWE
Given the small effect sizes obtained using FWE 0.05 
for MS subgroups compared to controls, we reran 
the analysis without FWE, using an alpha level of 
0.001, uncorrected. The results are shown in Table 3. 
Figure 1 illustrates the areas affected by MTR reduc-
tion and atrophy for each MS subgroup, compared to 
controls. We also reran the MS subgroup comparisons 
without FWE, using an alpha level of 0.001 uncor-
rected, and the summary of the findings are shown in 
Table 4. Supplementary Material, Appendices 5–9 
show the GM areas affected.
This suggests that in PPMS, there is considerably 
more MTR reduction than atrophy (24,615 voxels 
vs 1857 voxels respectively). SPMS shows the 
most widespread MTR reduction (97,707) and atro-
phy (30,153) of all the subgroups. The only differ-
ence seen compared to the analysis with FWE 
Table 3. Voxel-based analysis (VBA) significant voxel counts (compared with controls) by clinical subgroup and 
location (0.001, uncorrected).
Overall MTR reduction Overall atrophy
 RR SP PP RR SP PP
Total 53,672 97,707 24,615 27,903 30,153 1857
Cortex 38,049 80,051 20,917 9562 17,647 712
Deep GM 15,623 17,656 3698 18,341 12,506 1145
GM: grey matter; MTR: magnetisation transfer ratio; PP: primary progressive; RR: relapsing–remitting; SP: secondary progressive.
Figure 1. Voxel-based analysis (VBA) significant voxels (compared with controls) demonstrating magnetisation transfer 
ratio (MTR) reduction and atrophy by clinical subgroup (0.001, uncorrected). PPMS: primary progressive multiple 
sclerosis; RRMS: relapsing–remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis.
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correction (p=0.05) is in RRMS, which revealed a 
greater number of voxels showing MTR reduction 
compared to atrophy (53,672 voxels vs 27,903 
voxels).
Comparing MS subgroups (without FWE, using and 
alpha level of 0.001, uncorrected) reveals overall 
small differences in regions of MTR reduction and 
atrophy, and supports the findings from comparison 
with controls. Greater cortical MTR reduction and 
atrophy is seen in RRMS compared to PPMS, 
although PPMS subjects do also show MTR reduc-
tion in some cortical regions not seen in the RRMS 
subgroup. SPMS and RRMS comparisons reveal 
overall greater areas of MTR reduction and atrophy 
in the former, mainly in the cortex, although there are 
regions of MTR reduction and atrophy in RRMS not 
seen in the SPMS group. Similarly, when comparing 
SPMS and PPMS, while the latter does demonstrate 
greater MTR reduction in a few regions, overall 
SPMS subjects showed more MTR reduction and 
atrophy.
Co-localisation of MTR reduction and atrophy. Over-
laying the areas of MTR reduction and atrophy for 
each MS subgroup allowed us to estimate which areas 
of the GM demonstrate co-localisation of these mea-
sures, albeit in a non-statistically tested manner. The 
results of these are included in Supplementary Mate-
rial, Appendices 10–13.
Correlation analysis using BPM
The results of the within-group correlation analysis of 
volume and MTR are summarised in Table 5.
SPMS patients show the greatest number of GM vox-
els demonstrating either MTR reduction or atrophy, 
but only a small proportion of these voxels have sig-
nificant correlation between the two. RRMS patients 
also show a large number of GM voxels demonstrat-
ing either abnormality, the majority of which signifi-
cantly correlate. In PPMS patients, there are less GM 
voxels overall demonstrating either abnormality, but 
only a small proportion of these correlate signifi-
cantly. In all MS subgroups, there are more voxels 
demonstrating positive correlation between MTR 
and volume in the cortex compared to the deep GM. 
RRMS patients show the greatest number of correlat-
ing voxels overall in the GM, as well as proportion-
ately greatest deep GM involvement. In SPMS and 
PPMS patients there are far fewer positively correlat-
ing voxels overall, the vast majority of which are in 
the cortex.
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Discussion
MTR reduction is thought to reflect demyelination, as 
shown by histopathological work in cortical GM,19 as 
well as WM,18 and atrophy is predominantly second-
ary to neuro-axonal loss.11 Co-localisation of MTR 
reduction and atrophy would therefore suggest a link 
between demyelination and neuro-axonal loss. The 
presence of atrophy alone suggests neuro-axonal loss 
without demyelination. The presence of MTR reduc-
tion alone without significant atrophy co-localisation 
is suggestive of demyelination without significant 
neuronal loss.
In this study, the results reveal differences in the spa-
tial patterns of MTR reduction and atrophy in the MS 
cohort overall and between different clinical sub-
groups that may help improve our understanding of 
the pathophysiological basis of GM pathology in MS.
In all MS subgroups, MTR reduction was more exten-
sive than atrophy. Although absolute numbers of vox-
els demonstrating cortical MTR reduction was higher 
than in the deep GM, taking into consideration the 
mean voxel counts for cortical GM and deep GM in 
each group (Table 1), a greater proportion of the deep 
GM compartment showed MTR reduction compared 
with the cortex, in all subgroups, but especially in 
RRMS and SPMS subgroups. Atrophy was seen in 
both RRMS and SPMS subgroups, and both showed 
greater involvement of the deep GM than the cortex, 
relative to the respective sizes of the compartments.
Within-group correlation analysis suggests that in 
RRMS, there more abnormal voxels overall demon-
strating either MTR reduction or atrophy, and most 
of these demonstrating significant correlation 
between the two, with the deep GM showing espe-
cially high proportional involvement. In SPMS and 
PPMS the number of correlating voxels is less over-
all, with proportionately fewer correlating voxels in 
the deep GM.
These results suggest that there is significant neuro-
axonal loss, especially in the deep GM of the relapse-
onset groups (RRMS and SPMS). A previous VBM 
study of atrophy in the GM of early PPMS patients 
(within five years of symptom onset) demonstrated a 
shift in the pattern of atrophy as the disease pro-
gressed, with deep GM atrophy seen early on and 
greater involvement of the cortex later.36 In the pro-
gressive groups (SPMS and PPMS), there is propor-
tionately greater cortical demyelination, which is 
agreement with histopathological work.3,37 Further, 
this appears to be relatively greater in SPMS com-
pared with PPMS; cortical demyelination has recently 
been linked with meningeal inflammation, and in turn 
this is more evident in SPMS than PPMS.8,9
RRMS shows the greatest number of voxels demon-
strating correlation between MTR reduction and atro-
phy in the deep GM, which is consistent with previous 
histopathological work on relapse-onset MS.5 This 
suggests that, in the deep GM of this subgroup, demy-
elination and neuro-axonal loss may be linked. For 
instance, inflammatory demyelination in the deep 
GM may lead to secondary neuro-axonal loss, or per-
haps primary neurodegenerative neuro-axonal loss in 
the deep GM may lead to secondary loss of myelin. In 
SPMS patients, while there is increased demyelina-
tion and neuro-axonal loss overall, only a small 
amount of this co-exists in the same regions, espe-
cially in the deep GM. In PPMS patients, deep GM 
demyelination and neuro-axonal loss is seen, but to a 
lesser than in RRMS and SPMS patients, and correla-
tion is minimal. This suggests that in progressive MS 
the two pathologies are, for the most part, not due to a 
common process.
Although significant inflammation is usually seen in 
cortical demyelinating lesions in early MS, this is 
usually not so in MS of a longer duration.38–40 A 
recently published histopathological study suggested 
that the deep GM showed inflammation that is less 
Table 5. Number of voxels within each multiple sclerosis (MS) subgroup demonstrating positive correlation between 
magnetisation transfer ratio (MTR) and volume (family wise error (FWE) 0.05).
RRMS SPMS PPMS
Total GM voxels demonstrating either MTR 
or volume change
101,273 137,994 31,514
Total GM voxels demonstrating correlation 
between MTR and volume
98,046 2706 2034
Cortical GM voxels 85,599 2626 2030
Deep GM voxels 12,447 80 4
GM: grey matter; PP: primary progressive; RR: relapsing–remitting; SP: secondary progressive.
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than in the white matter but more than in the cortical 
GM.41 As demyelination usually occurs within the 
context of inflammation, this may explain why, in 
our study, the deep GM compartment showed rela-
tively greater amounts of demyelination compared to 
the cortex in all MS subgroups, proportional to the 
respective compartment sizes. Our results also sug-
gest that inflammatory demyelination plays a rela-
tively limited direct role in neuro-axonal loss, 
especially in the cortex of progressive MS. Atrophy 
may thus be either a primary neurodegenerative pro-
cess, or may be secondary to the downstream effects 
of WM inflammatory pathology without associated 
local demyelination.1
Our results need to be interpreted with respect to the 
methodology used. This was a cross-sectional study 
with a modest sample size, which may affect the gen-
eralisability of the findings. In PPMS patients the 
relatively small voxel counts overall may be a reflec-
tion of the relatively fewer subjects in this cohort. The 
use of FWE (p=0.05) produced results with small 
effect sizes, and this is likely a reflection of the con-
servative nature of the VBA analysis (which detects 
consistent group level changes rather than any voxel 
that is abnormal in any individual subject). For the 
MTR analysis we also used a threshold of 90% for 
GM extraction to limit partial volume effects. 
However, given that a substantial proportion of corti-
cal GM demyelination occurs in the subpial layers,3,9 
this may also have reduced the sensitivity to cortical 
demyelination. We also used a tissue segmentation 
pipeline optimised for MS, with lesion-filling prior to 
processing by SPM8, and custom built DARTEL tem-
plates, which have been shown to reduce artifactual 
changes in MS studies,42 but may also further reduce 
effect size. Using an uncorrected statistical threshold 
(p=0.001), results of the comparisons with controls 
were broadly consistent with those from the more 
stringent FWE (p=0.05) analysis, but with greater 
effect sizes, confirming that the choice of threshold 
does not substantially alter our main conclusions.
Conclusion
The results of this study suggest, that in RRMS 
patients, demyelination and neuro-axonal loss often 
occur in the same regions in the deep GM, implying 
that these two processes may be linked in this GM 
compartment. In progressive MS patients, co-existing 
demyelination and neuro-axonal loss was less com-
monly seen, which argues against these processes 
being linked. Overall, this study argues against a sin-
gle underlying mechanism as a cause of GM pathol-
ogy in MS clinical subgroups.
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